Market Introduction
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
Thus, the growing approvals for cell therapies is expected to create a significant demand for cell therapy bioprocessing in the coming years, which is further anticipated to drive the cell therapy bioprocessing market.
COVID-19 cases are increasing in South and Central America. With the outbreak of the second wave of COVID-19, the number of cases in SCAM countries has increased. Despite this impact, the region's biotechnology industry is doing little to fight the virus, and the lack of projects has exposed the sector's vulnerability. There are a few unrelated and autonomous projects going on, but they are happening independently of one another, meaning that there is no strong biotech network. Currently, Brazil has the second highest reported cases of COVID-19 infection across the world. Brazilian Association of Hematology, Hemotherapy and Cellular Therapy have constituted a panel of experts to carefully examine and review the use of cellular therapies for the treatment of COVID 19. Such an initiatives will bring significant growth for cell therapy bioprocessing market in long run.
Market Overview and Dynamics
The Cell therapy bioprocessing market in South and Central America is expected to grow from US$ 458.2 million in 2021 to US$ 994.7 million by 2028; it is estimated to grow at a CAGR of 11.7% from 2021 to 2028. Automated procedures will also help in scaling-up the production volumes and continuous production of different batches with minimal tracking. It will also increase productivity by enabling the rapid expansion of manufacturing capability. There have been several instances of companies developing automated processes. In July 2020, Thermo Fisher Scientific Inc., and Lyell Immunopharma entered a partnership to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve fitness of T-cells and support the development of an integrated cGMP compliant platform (system and software) along with reagents, consumables, and instruments. Likewise, in March 2019, Lonza entered a partnership with Israel’s Sheba Medical Center to provide automated and closed CAR-T manufacturing using its point-of-care Cocoon cell therapy manufacturing platform. Thus, the adoption of automated procedures will help overcome the challenges associated with cell therapy bioprocessing and offer growth opportunities to the market players that will contribute to the market growth in the coming years.
Key Market Segments
In terms of technology, the bioreactors segment accounted for the largest share of the South and Central America cell therapy bioprocessing market in 2020. In terms of cell type, the stem cell segment accounted for the largest share of the South and Central America cell therapy bioprocessing market in 2020. In terms of indication, the oncology segment accounted for the largest share of the South and Central America cell therapy bioprocessing market in 2020. In terms of end user, the academic and research institute segment held a larger market share of the cell therapy bioprocessing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Cell therapy bioprocessing market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc.
Reasons to buy report
SOUTH AND CENTRAL AMERICA CELL THERAPY BIOPROCESSING MARKET SEGMENTATION
By Technology
By Cell Type
By Indication
By End User
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 458.2 Million |
| Market Size by 2028 | US$ 994.7 Million |
| CAGR (2021 - 2028) | 11.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South and Central America Cell Therapy Bioprocessing Market is valued at US$ 458.2 Million in 2021, it is projected to reach US$ 994.7 Million by 2028.
As per our report South and Central America Cell Therapy Bioprocessing Market, the market size is valued at US$ 458.2 Million in 2021, projecting it to reach US$ 994.7 Million by 2028. This translates to a CAGR of approximately 11.7% during the forecast period.
The South and Central America Cell Therapy Bioprocessing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Cell Therapy Bioprocessing Market report:
The South and Central America Cell Therapy Bioprocessing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Cell Therapy Bioprocessing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Cell Therapy Bioprocessing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Cell Therapy Bioprocessing Market
